<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949165</url>
  </required_header>
  <id_info>
    <org_study_id>326045 - UG3HL151599</org_study_id>
    <secondary_id>UG3HL151599</secondary_id>
    <nct_id>NCT04949165</nct_id>
  </id_info>
  <brief_title>Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study</brief_title>
  <acronym>BLIS</acronym>
  <official_title>Iron Supplementation and Nutritional Counseling Interventions to Improve Availability and Safety of Blood in Ghana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Blood Service Ghana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ghana Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool School of Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syracuse University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study has 2 components: 1) a cross-sectional assessment designed to estimate the&#xD;
      prevalence of anaemia leading to donor deferral, the prevalence of iron deficiency (ID) and&#xD;
      iron deficiency anaemia (IDA) among first-time donors, and 2) a longitudinal 2-arm parallel&#xD;
      groups trial among first- time voluntary donors that compares haemoglobin levels at 4 months&#xD;
      among those with ID or IDA who receive iron supplementation to those without ID or IDA who do&#xD;
      not receive iron supplementation. A structured questionnaire will be used to extract&#xD;
      demographic characteristics. Participants will be followed for a total of 6 months with study&#xD;
      visits at 2, 4 and 6 months after the baseline assessments. Blood draws for full blood count&#xD;
      (FBC), peripheral film comment, malaria rapid diagnostic tests (RDT) and ferritin assessment&#xD;
      will occur at baseline and all follow-up visits. In addition, we will use a qualitative&#xD;
      approach to identify barriers and facilitators of blood donation and the use of dietary and&#xD;
      iron supplementation strategies to address iron deficiency and/or anaemia. This will involve&#xD;
      conducting focus group discussions during the last month of the intervention and key&#xD;
      informant interviews.&#xD;
&#xD;
      Expected Outcomes The expected outcomes of the study have been grouped into two, primary and&#xD;
      secondary. Primary Outcome will be haemoglobin level after 4 months. Secondary Outcomes are&#xD;
      A. Change in haemoglobin levels B. Diagnosis of ID or IDA at 4 months C. Serum ferritin&#xD;
      concentration after 4 months of intervention D. Acceptability of iron supplementation among&#xD;
      participants and stakeholders E. Incidence of gastrointestinal adverse events F. Incidence of&#xD;
      suspected malaria or bacterial infections G. Incidence of ID and IDA H. Successful return&#xD;
      (non-deferred) to the blood donor pool after intervention within 6 months of enrolment I. Key&#xD;
      barriers and facilitators of intervention implementation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemoglobin level</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>Iron-deficiency Anemia</condition>
  <condition>Iron-deficiency</condition>
  <arm_group>
    <arm_group_label>Iron Supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Iron Supplementation</intervention_name>
    <description>low dose ferrous sulphate (65mg elemental iron) supplements</description>
    <arm_group_label>Iron Supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females aged between 17 and 60 years who weigh at least 50kg. 17 BloodSafe&#xD;
             Ghana&#xD;
&#xD;
          2. Pass pre-donation screening using the NBSG standardised donor screening questionnaire&#xD;
             for medical conditions and lifestyle risks for transfusion transmissible infections&#xD;
             (Appendix 5).&#xD;
&#xD;
          3. Vital signs must meet the NBSG requirement for blood donation: systolic and diastolic&#xD;
             blood pressures between 90-140 mmHg and 60- 90 mmHg, respectively; pulse rate between&#xD;
             50-100 bpm; non-contact forehead temperature not exceeding 37.5Â°C; meeting acceptable&#xD;
             requirements for skin lesions, needle marks and physical appearance.&#xD;
&#xD;
          4. Must be willing and able to give study consent or assent.&#xD;
&#xD;
          5. Intend to remain in the study location/site during the entire length of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. 2. 3. 4. 5. items 1-5 pertain to the clinical trial. All persons who meet ANY of the&#xD;
        exclusion criteria will be excluded from participating in the clinical trial.&#xD;
&#xD;
        Persons who have used iron supplementation within the past one month. Participant reports&#xD;
        having previously donated blood. Evidence for a TTI at baseline among those who&#xD;
        successfully donated. Evidence of Malaria and helminthic infections at baseline&#xD;
        Participants who have Hb &lt;10g/dl at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susan E Telke, MS</last_name>
    <phone>6126249644</phone>
    <email>telke001@umn.edu</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood donation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The BLOODSAFE project is committed to quickly sharing results and data. Papers will be submitted summarizing the primary results of the BLOODSAFE studies once the analysis is complete. These results will be published in major scientific journals and presented at scientific meetings.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

